These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
353 related articles for article (PubMed ID: 18467239)
21. Irinotecan and uridine diphosphate glucuronosyltransferase 1A1 pharmacogenetics: to test or not to test, that is the question. Deeken JF; Slack R; Marshall JL Cancer; 2008 Oct; 113(7):1502-10. PubMed ID: 18720361 [TBL] [Abstract][Full Text] [Related]
22. UGT1A1*6 polymorphisms are correlated with irinotecan-induced neutropenia: a systematic review and meta-analysis. Zhang X; Yin JF; Zhang J; Kong SJ; Zhang HY; Chen XM Cancer Chemother Pharmacol; 2017 Jul; 80(1):135-149. PubMed ID: 28585035 [TBL] [Abstract][Full Text] [Related]
23. Pharmacogenetics and irinotecan therapy. Hahn KK; Wolff JJ; Kolesar JM Am J Health Syst Pharm; 2006 Nov; 63(22):2211-7. PubMed ID: 17090741 [TBL] [Abstract][Full Text] [Related]
24. Importance of UDP-glucuronosyltransferase 1A1*6 for irinotecan toxicities in Japanese cancer patients. Sai K; Saito Y; Sakamoto H; Shirao K; Kurose K; Saeki M; Ozawa S; Kaniwa N; Hirohashi S; Saijo N; Sawada J; Yoshida T Cancer Lett; 2008 Mar; 261(2):165-71. PubMed ID: 18082937 [TBL] [Abstract][Full Text] [Related]
25. UGT1A1 promoter genotype correlates with SN-38 pharmacokinetics, but not severe toxicity in patients receiving low-dose irinotecan. Stewart CF; Panetta JC; O'Shaughnessy MA; Throm SL; Fraga CH; Owens T; Liu T; Billups C; Rodriguez-Galindo C; Gajjar A; Furman WL; McGregor LM J Clin Oncol; 2007 Jun; 25(18):2594-600. PubMed ID: 17577039 [TBL] [Abstract][Full Text] [Related]
26. Clinical observations on associations between the UGT1A1 genotype and severe toxicity of irinotecan. Lu YY; Huang XE; Wu XY; Cao J; Liu J; Wang L; Xiang J Asian Pac J Cancer Prev; 2014; 15(7):3335-41. PubMed ID: 24815493 [TBL] [Abstract][Full Text] [Related]
27. Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. Innocenti F; Undevia SD; Iyer L; Chen PX; Das S; Kocherginsky M; Karrison T; Janisch L; Ramírez J; Rudin CM; Vokes EE; Ratain MJ J Clin Oncol; 2004 Apr; 22(8):1382-8. PubMed ID: 15007088 [TBL] [Abstract][Full Text] [Related]
28. UGT1A1 polymorphisms with irinotecan-induced toxicities and treatment outcome in Asians with Lung Cancer: a meta-analysis. Chen X; Liu L; Guo Z; Liang W; He J; Huang L; Deng Q; Tang H; Pan H; Guo M; Liu Y; He Q; He J Cancer Chemother Pharmacol; 2017 Jun; 79(6):1109-1117. PubMed ID: 28502040 [TBL] [Abstract][Full Text] [Related]
29. Prolonged neutropenia after irinotecan-based chemotherapy in a child with polymorphisms of UGT1A1 and SLCO1B1. Sakaguchi S; Garcia-Bournissen F; Kim R; Schwarz UI; Nathan PC; Ito S Arch Dis Child; 2009 Dec; 94(12):981-2. PubMed ID: 19608554 [TBL] [Abstract][Full Text] [Related]
30. Effects of Shengjiangxiexin decoction on irinotecan-induced toxicity in patients with UGT1A1*28 and UGT1A1*6 polymorphisms. Deng B; Jia L; Tan H; Lou Y; Li X; Li Y; Yu L J Tradit Chin Med; 2017 Feb; 37(1):35-42. PubMed ID: 29956901 [TBL] [Abstract][Full Text] [Related]
31. UGT1AI*6 and UGT1A1*27 for individualized irinotecan chemotherapy. Ando Y; Fujita K; Sasaki Y; Hasegawa Y Curr Opin Mol Ther; 2007 Jun; 9(3):258-62. PubMed ID: 17608024 [TBL] [Abstract][Full Text] [Related]
32. UGT1A7 and UGT1A9 polymorphisms predict response and toxicity in colorectal cancer patients treated with capecitabine/irinotecan. Carlini LE; Meropol NJ; Bever J; Andria ML; Hill T; Gold P; Rogatko A; Wang H; Blanchard RL Clin Cancer Res; 2005 Feb; 11(3):1226-36. PubMed ID: 15709193 [TBL] [Abstract][Full Text] [Related]
33. Associations between UGT1A1*6/*28 polymorphisms and irinotecan-induced severe toxicity in Chinese gastric or esophageal cancer patients. Gao J; Zhou J; Li Y; Peng Z; Li Y; Wang X; Shen L Med Oncol; 2013; 30(3):630. PubMed ID: 23783485 [TBL] [Abstract][Full Text] [Related]
34. Screening for adverse reactions to irinotecan treatment using the Invader UGT1A1 Molecular Assay. Hasegawa Y; Ando Y; Shimokata K Expert Rev Mol Diagn; 2006 Jul; 6(4):527-33. PubMed ID: 16824027 [TBL] [Abstract][Full Text] [Related]
35. [UGT1A1 Genotyping for Proper Use of Irinotecan]. Matsuoka A; Ando Y Rinsho Byori; 2015 Jul; 63(7):876-82. PubMed ID: 26591441 [TBL] [Abstract][Full Text] [Related]
36. The association of UGT1A1*6 and UGT1A1*28 with irinotecan-induced neutropenia in Asians: a meta-analysis. Chen YJ; Hu F; Li CY; Fang JM; Chu L; Zhang X; Xu Q Biomarkers; 2014 Feb; 19(1):56-62. PubMed ID: 24308720 [TBL] [Abstract][Full Text] [Related]
37. [Examination of factors affecting adverse reactions and dosage reduction in UGT1A1 genotyped patients: a retrospective survey of irinotecan]. Okazaki K; Watanabe T; Saito I; Murayama J Yakugaku Zasshi; 2012; 132(2):231-6. PubMed ID: 22293705 [TBL] [Abstract][Full Text] [Related]
38. The power of genes: a case of unusually severe systemic toxicity after localized hepatic chemoembolization with irinotecan-eluted microspheres for metastatic colon cancer. Cruz JE; Saksena R; Jabbour SK; Nosher JL; Hermes-DeSantis E; Moss RA Ann Pharmacother; 2014 Dec; 48(12):1646-50. PubMed ID: 25202035 [TBL] [Abstract][Full Text] [Related]
39. Phase I study of irinotecan for previously treated lung cancer patients with the UGT1A1*28 or *6 polymorphism: Results of the Lung Oncology Group in Kyushu (LOGIK1004A). Fukuda M; Shimada M; Kitazaki T; Nagashima S; Hashiguchi K; Ebi N; Takayama K; Nakanishi Y; Semba H; Harada T; Seto T; Okamoto I; Ichinose Y; Sugio K Thorac Cancer; 2017 Jan; 8(1):40-45. PubMed ID: 27883280 [TBL] [Abstract][Full Text] [Related]
40. [Relationship between UGT1A and irinotecan-related toxicity]. Xu JM Zhonghua Zhong Liu Za Zhi; 2013 Apr; 35(4):241-3. PubMed ID: 23985249 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]